🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

An International Public Health Issue

Gonorrhoea infections are escalating around the world, with estimates suggesting more than 82 million new cases per year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Gain Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Data and Global Access

Based on findings published in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which involves a dual-drug approach. The study involved over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to license and sell the drug in many low-income and middle-income countries.

Clinicians directly involved have expressed positive views. Having a one-pill regimen such as this is described as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.